Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations

Core Insights - Femasys, Inc. has announced a partnership with CNY Fertility to provide its FemaSeed intratubal insemination product as a treatment option for infertility across CNY Fertility's 11 locations [1][2] Company Overview - Femasys is a biomedical innovator focused on women's health, offering a range of therapeutic and diagnostic products that are disruptive and accessible [4] - The company has received regulatory approvals for its product portfolio worldwide, including FDA clearance for FemaSeed in the U.S. and approvals in Europe, UK, Canada, and Israel [4] Product Details - FemaSeed is designed to enhance fertilization by delivering sperm directly into the fallopian tube, providing a safe and cost-effective first-line option for couples facing infertility [3] - The product serves as an alternative to intrauterine insemination (IUI) and is positioned as a less burdensome step before in vitro fertilization (IVF) [3] Partnership Significance - The partnership with CNY Fertility aims to expand access to FemaSeed, aligning with CNY's mission to provide comprehensive and affordable fertility solutions [2][6] - CNY Fertility has a strong track record, having helped create over 30,000 lives since its inception in 1997, emphasizing its commitment to accessible fertility treatments [6]